Predicine
Predicine is a biotech company specializing in genomic profiling tests and algorithms for cancer diagnostics and monitoring, utilizing a liquid biopsy platform and operating CLIA-certified laboratories in the US and China.
Genomic Profiling Tests for Cancer Diagnostics
Predicine offers a range of genomic profiling tests that leverage robust algorithms to aid in cancer diagnostics and monitoring. The tests utilize next-generation sequencing technologies to provide molecular insights into various types of cancer. Some of the key assays offered by Predicine include PredicineATLAS™, PredicineCARE™, PredicineRNA™, PredicineHEME™, PredicineBEACON™, and PredicineWES+™, each designed to deliver comprehensive cancer profiling.
Liquid Biopsy Platform for Cancer Detection
Predicine utilizes an advanced liquid biopsy platform that analyzes both cell-free DNA (cfDNA) and RNA (cfRNA) from blood or urine samples. This methodology allows for non-invasive detection and monitoring of cancer. The company’s urine-based liquid biopsy is particularly robust in the detection of genitourinary cancers, providing a valuable tool for non-invasive cancer diagnostics.
State-of-the-Art Laboratories
Predicine operates CLIA-certified and CAP-accredited laboratories in the United States and China. These laboratories are equipped with the latest technologies to ensure high standards of accuracy and reliability in their diagnostic services. The certifications affirm the company’s commitment to maintaining quality and consistency in their laboratory operations.
GeneRADAR Platform for Comprehensive Analysis
The proprietary GeneRADAR platform developed by Predicine offers a unique approach to measure both the genomic blueprint and functional biology of cancer in a single tube of blood. This platform provides a comprehensive analysis that can guide the development of personalized treatment plans for cancer patients.
AI-Driven Bioinformatics for Genomic Data Analysis
Predicine employs AI-driven bioinformatics to analyze complex genomic data. This advanced approach allows for the interpretation of vast amounts of genomic information, aiding in the identification of biomarkers and supporting biomarker-driven clinical trials from Phase I to III. This enhances the precision in cancer diagnosis and treatment planning.